Europe COPD & Asthma Devices Market

According to a recently published report by KBV Research, the Europe COPD & Asthma Device Market attained a market size of $ 5,522.2 Million in 2015 and is expected to reach $ 7,419.8 Million by 2022 growing at a CAGR of 4.4 % CAGR during 2016 - 2022.
The Russia market dominated the Europe COPD & Asthma Device Market in 2015 and would continue till 2022 growing at a CAGR of 2.7 % during the forecast period. The Germany market is expected to reach a market size of $ 1,246.5 Million by 2022. The UK market would witness the high growth rate of 5.4 % during 2016-2022.
The Inhalers market dominated the Russia COPD and Asthma Devices Market in 2015 and would continue till 2022 thereby achieving a market value of $ 1,553.6 Million by 2022 growing at a CAGR of 2.8 % during the forecast period.
The report highlights the adoption of COPD & Asthma Devices in Europe. Based on the product type; the market is segmented into Inhalers and Nebulizers market. Further the Inhaler segment is sub segmented into Dry Powder Inhalers, Metered Dose Inhalers and Soft Mist Inhalers Market. The Nebulizers segment is bifurcated into Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers Market. The Countries included in the report are Russia, Germany, UK, France, Spain, Italy and Rest of Europe.
Key players profiled in the report include Glaxosmithcline PLC., Novartis International AG., Biotronik SE & Co. KG., AstraZeneca Plc., 3M Healthcare, GF Health Products, Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Inc., Baxter International and Philips.